|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 543.00 JPY | +17.28% |
|
+41.04% | - |
| 07-02 | Innovacell Secures U.S. Clearance for Global Phase III Cell Therapy Clinical Trial | MT |
| 05-13 | Innovacell Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 | CI |
| Market Cap | 24.49B 152M 133M 122M 114M 216M 14.46B 219M 1.46B 569M 7.11B 570M 558M | P/E 2026 * |
-6.66x | P/E 2027 * | -6.28x |
|---|---|---|---|---|---|
| Enterprise Value | 24.49B 152M 133M 122M 114M 216M 14.46B 219M 1.46B 569M 7.11B 570M 558M | EV / Sales 2026 * |
24.5x | EV / Sales 2027 * | 22.7x |
| Free-Float |
52.14% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | +17.28% | ||
| 1 week | +41.04% | ||
| Current month | +32.44% | ||
| 1 month | -0.18% | ||
| 3 months | -32.96% |
| 1 week | 395 |  | 543 |
| 1 month | 377 | | 710 |
| Current year | 377 | | 1,248 |
| 1 year | 377 | | 1,248 |
| 3 years | 377 | | 1,248 |
| 5 years | 377 | | 1,248 |
| 10 years | 377 | | 1,248 |
| Manager | Title | Age | Since |
|---|---|---|---|
Colin Lee Novick
CEO | Chief Executive Officer | 45 | 01/03/2022 |
Jason Sieger
CEO | Chief Executive Officer | 43 | 01/03/2025 |
Yasushi Hosono
DFI | Director of Finance/CFO | 59 | 01/07/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Jason Sieger
BRD | Director/Board Member | 43 | 01/01/2021 |
Colin Lee Novick
BRD | Director/Board Member | 45 | 01/07/2021 |
| Director/Board Member | 56 | 01/04/2021 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +17.28% | +41.04% | - | - | 152M | |
| +1.86% | +0.48% | +55.50% | +163.08% | 1,082B | |
| +3.57% | +3.29% | +68.60% | +61.03% | 633B | |
| +3.99% | +3.05% | +37.93% | +93.37% | 461B | |
| +3.86% | +1.64% | +32.57% | +24.89% | 338B | |
| -0.56% | +0.96% | +41.67% | +39.35% | 299B | |
| -0.08% | +1.30% | +32.15% | +44.48% | 291B | |
| -1.54% | +2.81% | -25.35% | -39.61% | 222B | |
| +3.55% | +4.41% | +25.45% | +66.28% | 202B | |
| +4.21% | +2.65% | +17.47% | +71.11% | 163B | |
| Average | +3.61% | +8.22% | +31.78% | +58.22% | 369.25B | |
| Weighted average by Cap. | +2.25% | +5.53% | +42.31% | +83.31% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1B 6.2M 5.42M 4.98M 4.64M 8.81M 590M 8.94M 59.8M 23.25M 290M 23.27M 22.77M | 1.08B 6.68M 5.84M 5.37M 5.01M 9.49M 636M 9.64M 64.47M 25.06M 313M 25.09M 24.55M |
| Net income | -3.46B -21.47M -18.77M -17.25M -16.08M -30.5M -2.04B -30.96M -207M -80.51M -1B -80.6M -78.87M | -3.81B -23.61M -20.64M -18.97M -17.68M -33.54M -2.25B -34.05M -228M -88.53M -1.11B -88.63M -86.72M |
| Net Debt | - | - |
Employees
48
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/07/26 | ¥543.00 | +17.28% | 12,900 |
| 02/07/26 | ¥463.00 | +11.84% | 209,400 |
| 01/07/26 | ¥414.00 | +0.98% | 35,000 |
| 30/06/26 | ¥410.00 | +2.50% | 45,700 |
| 29/06/26 | ¥400.00 | +3.90% | 73,800 |
Annual profits - Rate of surprise
- Stock Market
- Stocks
- 504A Stock
Select your edition
All financial news and data tailored to specific country editions
